Patent · US Active

Dimer VEGF antagonist formulations

US8404638B2 · kind B2 · utility

47Cited by

13References

8Claims

0Family size

Assignee

REGENERON PHARMACEUTICALS, INC. · US

Inventors

Daniel Dix · Lagrangeville, US
Kelly Frye · Mendham, US
Susan KAUTZ · Albany, US

Key dates

Filing date	Jan 4, 2012
Grant date	Mar 26, 2013
Priority date	—
Expiry date	Jan 4, 2032

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.